RSV D486N-mut. fusion protein inh.

oral antiviral clinical candidate

from lower barrier to atropisomerism of lead

Bioorg. Med. Chem., Oct. 31, 2020

Taisho Pharmaceutical, Saitama, JP

Structure of compound 60b

“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: